Ana Pena, PhD

Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.

At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.

Articles by Ana Pena, PhD

MYELOMA

FDA Asked to Approve Darzalex Triple Combo for Relapsed or Refractory Multiple Myeloma

Janssen has asked the U.S. Food and Drug Administration (FDA) to…

MYELOMA

Bone Marrow Macrophages Could Predict Resistance to Velcade, Study Suggests

The multiple myeloma therapy Velcade (bortezomib) can induce the formation of pro-inflammatory macrophages — a kind…

MYELOMA

Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests

A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous…

MYELOMA

CAR T-Cell Candidate bb2121 Shows Promise in Heavily Pre-treated Myeloma, Interim Data Show

The candidate CAR-T cell therapy bb2121 showed a favorable…

MYELOMA

Pivotal OPTIMISMM Trial Shows Benefits of Pomalyst Triple Combo Therapy

Treatment with Pomalyst (pomalidomide) in combination with Velcade (bortezomib) and dexamethasone…

MYELOMA

Revlimid and Imnovid Triple Combos Approved in EU for Adults with Multiple Myeloma

The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (…

MYELOMA

Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show

Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma…

MYELOMA

Kyprolis Combo Yields Positive Results as Initial Treatment for Multiple Myeloma

A combination of Kyprolis (carfilzomib) and dexamethasone, already approved for relapsed and refractory multiple…

MYELOMA

FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma

The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101,…

MYELOMA

New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study

A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed…